Interleukin‐2 activated human killer lymphocytes: Lack of involvement of interferon in the development of IL‐2‐activated killer lymphocytes
- 15 October 1987
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 40 (4) , 519-524
- https://doi.org/10.1002/ijc.2910400415
Abstract
When cultured with native or recombinant interleukin‐2 (IL‐2) human small agranular lymphocytes acquire the ability to kill various tumor targets. The development of these IL‐2 activated killer (IAK) cells, also known as LAK, is observed in the absence of antigen or mitogen. Interferons are known to augment the lytic effects of natural killer cells and cytolytic T lymphocytes. Our study was undertaken to examine the effect of human α, β, and γ interferons on the induction and the effector phase of IAK function. When cultured with small lymphoid cells IFN alone did not induce anti‐tumor cytolytic activity in those lymphocytes. Despite their known anti‐proliferative effects, none of the 3 IFN species at any concentrations tested inhibited the development of IAK activity when present during the entire culture period. IFN neither inhibited nor augmented the development of IAK cells under suboptimal conditions. Furthermore, activation of IAK cells was not affected by the presence of neutralizing antibodies to either α or γ IFN. Post‐activation exposure of IAK cells to IFN also failed to either augment or inhibit their lytic activity. Thus, neither endogenously generated nor exogenously added IFN had any effect on the IAK system, in contrast to their augmenting effects on NK cells and CTL.This publication has 36 references indexed in Scilit:
- Surface markers of human lymphokine-activated killer cells and their precursors. Analysis at the population and clonal levelInternational Journal of Cancer, 1987
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Enhancement of Human Allogeneic Cytotoxic Responses by InterferonsJournal of Immunopharmacology, 1985
- Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coliScience, 1984
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicityNature, 1979
- Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.The Journal of Experimental Medicine, 1978